Tag: clinical trials
-
NantHealth, TransMed Partner on Cancer Genomics
Two companies offering medical analytics aim to provide cancer specialists with individualized genomic analyses for their patients, and more access to clinical trials.
-
Trial to Test Radio Waves to Treat Alzheimer’s
A clinical trial is inviting individuals with Alzheimer’s disease to test a device that its designers claim can reverse cognitive impairment resulting from Alzheimer’s disease.
-
High Leukemia Remissions Reported for Engineered T-Cells
First results from an international clinical trial of engineered immune system cells to treat leukemia in children show high rates of remission, but also many severe adverse effects.
-
Stem Cell Therapy Shows Early Results with Multiple Myeloma
First results from an early clinical trial show some patients with multiple myeloma receiving replacement blood-forming stem cells achieved at least a partial response and did not suffer severe adverse effects.
-
Liquid Biopsy Better Detects Lung Cancer Mutations
Tests of blood and urine from patients with a common form of lung cancer show these liquid biopsies more accurately identified cancer-causing mutations than traditional tissue sample biopsies.
-
Engineered T-Cell Trial Halted After Participant Dies
A clinical trial testing treatments that modify immune system cells to fight leukemia in adults was stopped after one of the patients died from inflammation in the brain.
-
Partnership Assessing Nerve Stimulation Bleeding Device
The Feinstein Institute for Medical Research and Global Good Fund are evaluating an electronic device that stimulates nerves to stop bleeding, as a way to control postpartum hemorrhage
-
Targeted Leukemia Drugs Sharply Raising Costs of Care
Drugs directly attacking cancer cell growth show high remission rates with a common form of leukemia, but a new study suggests the high costs of these drugs could impose difficult economic burdens on patients and the health care system.
-
Novartis Acquires Sickle-Cell Drug Developer
Drug maker Novartis is acquiring Selexys Pharmaceuticals Corp., a developer of treatments for pain episodes associated with sickle cell disease, for $665 million.
-
Trial Shows Antibody Reduces Days with Migraines
First results from a late-stage clinical trial shows a synthetic antibody reduces the number of days with migraines per month among people with episodic or infrequent migraines.